Assessing ADMA Biologics (ADMA) Valuation After Rebuttal To Short Seller Allegations

Simply Wall St.03-31

ADMA Biologics (ADMA) moved back into focus after its shares climbed about 11% following a detailed rebuttal to a short seller report that questioned ASCENIV demand and alleged aggressive distribution...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2623374927?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-03-31 11:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623374927","market":"nz","top_or_hot":-1,"title":"Assessing ADMA Biologics (ADMA) Valuation After Rebuttal To Short Seller Allegations","media":"Simply Wall St.","content":"<div>\n<p>ADMA Biologics (ADMA) moved back into focus after its shares climbed about 11% following a detailed rebuttal to a short seller report that questioned ASCENIV demand and alleged aggressive distribution...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adma/adma-biologics/news/assessing-adma-biologics-adma-valuation-after-rebuttal-to-sh\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing ADMA Biologics (ADMA) Valuation After Rebuttal To Short Seller Allegations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing ADMA Biologics (ADMA) Valuation After Rebuttal To Short Seller Allegations\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-31 11:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adma/adma-biologics/news/assessing-adma-biologics-adma-valuation-after-rebuttal-to-sh><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ADMA Biologics (ADMA) moved back into focus after its shares climbed about 11% following a detailed rebuttal to a short seller report that questioned ASCENIV demand and alleged aggressive distribution...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adma/adma-biologics/news/assessing-adma-biologics-adma-valuation-after-rebuttal-to-sh\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adma/adma-biologics/news/assessing-adma-biologics-adma-valuation-after-rebuttal-to-sh","article_id":"2623374927","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adma/adma-biologics/news/assessing-adma-biologics-adma-valuation-after-rebuttal-to-sh","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2623374927","pubTimestamp":1774926935,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"ADMA Biologics (ADMA) moved back into focus after its shares climbed about 11% following a detailed rebuttal to a short seller report that questioned ASCENIV demand and alleged aggressive distribution practices.\nSee our latest analysis for ADMA Biologics.\nThat sharp 11% rebound sits against a weak recent trend, with a 30-day share price return of 41.23% and a year to date share price return of 48.83%. At the same time, the 3-year total shareholder return of about 1.8x and 5-year total...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ADMA":"ADMA Biologics Inc"},"translate_title":"反驳卖空者指控后评估ADMA Biologics(ADMA)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADMA":1.5},"content_text":"ADMA Biologics (ADMA) moved back into focus after its shares climbed about 11% following a detailed rebuttal to a short seller report that questioned ASCENIV demand and alleged aggressive distribution practices. See our latest analysis for ADMA Biologics. That sharp 11% rebound sits against a weak recent trend, with a 30-day share price return of 41.23% and a year to date share price return of 48.83%. At the same time, the 3-year total shareholder return of about 1.8x and 5-year total shareholder return of 4x point to a very different longer term story. If this kind of volatility has your attention, it can be a good moment to widen your watchlist and check out 34 healthcare AI stocks With ADMA Biologics trading at US$9.15, sitting on long term returns of about 1.8x over 3 years and 4x over 5 years, investors may be asking whether the current pullback is an entry point or if markets are already pricing in future growth. AdvertisementMost Popular Narrative: 56.3% Undervalued According to the most followed narrative, ADMA Biologics' fair value sits at $20.93 based on a discounted cash flow framework, versus the last close at $9.15, which sets up a wide valuation gap that rests on specific growth and margin assumptions.  I assume ADMA can generate 1 BUSD in revenues by 2029 (S29) with FCF margin 35% (FCF29 = 350 MUSD) and net profit margin of 30% (E29 = 300 MUSD)  Read the complete narrative. Curious what turns today’s revenue base into that higher earnings profile and supports a higher valuation multiple over time? The narrative leans on a tight mix of revenue growth, margin expansion and a specific discount rate, plus assumptions about how the market might value those future profits. The full breakdown shows exactly which operating levers need to fire together for that fair value to hold. Result: Fair Value of $20.93 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this upside case still hinges on ASCENIV demand holding up and management hitting margin and yield targets. Any stumble could quickly challenge that fair value narrative. Find out about the key risks to this ADMA Biologics narrative. Next Steps With sentiment clearly split between upside potential and real concerns, this is a good moment to review the facts, act promptly, and decide where you stand by weighing the 3 key rewards and 2 important warning signs Looking for more investment ideas? If this ADMA story has you thinking more broadly about your portfolio, now is the time to line up fresh ideas instead of waiting on the sidelines.  Target potential mispricings by scanning 62 high quality undervalued stocks and see which companies the market might be overlooking right now. Strengthen your income stream by reviewing 12 dividend fortresses that focus on higher yield opportunities. Prioritise resilience by checking 62 resilient stocks with low risk scores so your next idea is built on a steadier foundation.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2623374927","isCrawlerRequest":true}